Savara Inc. (SVRA) AI Stock Analysis

Savara Inc., headquartered in Austin, Texas, is a biopharmaceutical company specializing in the development of treatments for rare respiratory diseases. At the forefront of its pipeline is molgramostim, an innovative inhaled therapy based on granulocyte-macrophage colony-stimulating factor. Molgramostim is advancing through Phase III clinical trials to treat autoimmune pulmonary alveolar proteinosis (PAP). Beyond its lead candidate, the company explores additional therapeutic avenues to address unmet needs in respiratory medicine through scientific innovation, clinical research, and collaboration with medical professionals, researchers, and patient advocacy groups.

Savara recorded trailing twelve months revenue of $1,000 as of the latest quarter ended June 30, 2026, with an operating margin of 0.0% and EPS of -$0.58. In FY2021, revenue dropped 99.6% to $1,000 from $257,000 in FY2020, while net loss was -$43.0M alongside an R&D expense of $29.0M. Earlier, revenue was $400,000 in FY2016 and $54 in FY2015. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $1.8M and an EPS loss of -$0.65. For the next fiscal year, analysts forecast revenue to expand by 4406.1% to $80.7M, alongside an improved EPS estimate of -$0.37.

As of June 30, 2026, Savara held $173.0M in cash and short-term investments against total debt of $30.1M, yielding net cash of $142.9M. Total assets stood at $192.1M and shareholders' equity was $143.7M. The company maintains a current ratio of 10.13 and a debt-to-equity ratio of 0.21. In FY2025, capital expenditures were $22,000 and share buybacks totaled $5.1M, while share count expanded 66.2% over a 5-year period.

Savara carries a market capitalization of $914.3M and an enterprise value of $886.7M. The stock trades at a price-to-book ratio of 7.2x and a forward P/E of 0.4x, compared to a forward P/E median of 17.3x and a trailing P/E median of 24.6x for the median of its US-listed Healthcare peers. Over the past year, SVRA rose 24.3%, outpacing the 16.8% return of the S&P 500 benchmark. Over a 5-year span, the shares gained 245.0% compared to 83.0% for the index, though the stock has declined 26.2% year-to-date.

Wall Street coverage on Savara includes 6 Strong Buy and 3 Buy recommendations, with 0 Hold, Sell, or Strong Sell ratings. The mean price target is $11.06, reflecting a 148.4% premium over the last close of $4.45. Savara recorded 0 EPS beats over the last 4 quarters. The next earnings date is scheduled for November 11, 2026.

This page is an AI-written research summary of Savara Inc. (SVRA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SVRA income statement, SVRA balance sheet, SVRA key metrics, SVRA analyst forecast, SVRA chart. See the SVRA stock overview for the latest quote and news.